Q-omics provides the consensus-scored CD40 profile across patient tissues and cancer cell-line models. CD40 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CD40 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CD40 protein abundance shows 22,220 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight SKCM, KIRC, and CCRCC as cancer lineages where CD40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD40 survival associations across molecular data types. CD40 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD40 RNA expression–survival associations across cancer types. High CD40 expression shows unfavorable associations in LGG, but favorable associations in SKCM, LUAD, SARC, UCS and ACC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CD40 RNA expression.
This table summarizes CD40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD40 shows lower tumor expression in LUAD, UCEC, BRCA and LUSC and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher CD40 RNA expression in tumor versus normal tissue (log2 FC = +2.015, t-test p < 0.001).
This table shows molecular features associated with CD40 in patient tissues and cancer cell lines. In patient samples, CD40 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD40 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
